Pharmacological subgroup
B02B – VITAMIN K UND ANDERE HÄMOSTATIKA
26Decisions
28Patient groups
Added benefit by patient group
- Considerable1
- Non-quantifiable3
- Not proven24
Subgroups
- B02BD Blutgerinnungsfaktoren 13 decisions
- B02BX Andere systemische Hämostatika 13 decisions
Decisions, newest first
- 2026-03-19AlhemoConcizumabNot proven
- 2026-03-19AlhemoConcizumabNot proven
- 2025-10-16AlhemoConcizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2025-10-16AlhemoConcizumabNot proven
- 2025-07-17HympavziMarstacimabNot proven
- 2025-07-17HympavziMarstacimabNot proven
- 2024-02-15RefixiaNonacog beta pegolNot proven
- 2024-02-01AlprolixEftrenonacog alfaNot proven
- 2023-10-19HemgenixEtranacogen DezaparvovecNon-quantifiable
- 2023-08-17HemlibraEmicizumabNot proven
- 2023-03-16RoctavianValoctocogen roxaparvovecNon-quantifiable
- 2022-05-19Mulpleo (previously Lusutrombopag Shionogi)LusutrombopagNot proven
- 2022-04-07IdelvionAlbutrepenonacog alfaNot proven
- 2021-09-16DopteletAvatrombopagNot proven
- 2021-09-16DopteletAvatrombopagNot proven
- 2020-12-17TavlesseFostamatinibNot proven
- 2020-02-06EsperoctTuroctocog alfa pegolNot proven
- 2019-09-05HemlibraEmicizumabNot proven
- 2019-06-20JiviDamoctocog alfa pegolNot proven
- 2018-11-01AdynoviRurioctocog alfa pegolNot proven
- 2018-09-20HemlibraEmicizumabNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2018-04-19RefixiaNonacog beta pegolNot proven
- 2017-07-20AfstylaLonoctocog alfaNot proven
- 2016-06-16EloctaEfmoroctocog alfaNot proven
- 2015-05-07NuwiqSimoctocog alfaNot proven
- 2014-07-03NovoEightTuroctocog alfaNot proven
Data status: 2026-10-29